Ï㽶ÊÓƵ

Perry F. Renshaw
No Rating Available
(Learn About Our Rating System)

Perry F. Renshaw, MD, PhD, MBA

Languages spoken: English

  • Perry Renshaw, MD, PhD, MBA, is a graduate of the Ï㽶ÊÓƵ of Pennsylvania Perelman School of Medicine in Philadelphia, PA. He also completed his PhD in Biophysics at the Ï㽶ÊÓƵ of Pennsylvania and his MBA at the McCallum Graduate School of Business, Bentley College, in Waltham, MA. Dr. Renshaw serves as the Medical Director of the VISN 19 Mental Illness Research, Education and Clinical Center (MIRECC) at the Salt Lake City Veterans Affairs Medical Center. His training as a biophysicist and psychiatrist has led to a primary research interest in the use of multinuclear magnetic resonance spectroscopy (MRS) neuroimaging to identify changes in brain chemistry associated with psychiatric disorders and substance abuse. Over the past 20 years, he has conducted more than 1,000 MRS brain scans of individuals with mood disorders, with the goal of characterizing the cross-sectional and longitudinal alterations in brain chemistry associated with mood disorders and their treatment. As Professor in the Department of Psychiatry, he has a notable publication record having served as an author on more than 300 publications. His research projects have been funded by the NIH for 18 years, including a NIDA K05 and a collaborative R01 grant.

    Specialties

    Board Certification

    American Board of Psychiatry & Neurology (Psychiatry)

  • Perry Renshaw, MD, PhD, MBA, is a graduate of the Ï㽶ÊÓƵ of Pennsylvania Perelman School of Medicine in Philadelphia, PA. He also completed his PhD in Biophysics at the Ï㽶ÊÓƵ of Pennsylvania and his MBA at the McCallum Graduate School of Business, Bentley College, in Waltham, MA. Dr. Renshaw serves as the Medical Director of the VISN 19 Mental Illness Research, Education and Clinical Center (MIRECC) at the Salt Lake City Veterans Affairs Medical Center. His training as a biophysicist and psychiatrist has led to a primary research interest in the use of multinuclear magnetic resonance spectroscopy (MRS) neuroimaging to identify changes in brain chemistry associated with psychiatric disorders and substance abuse. Over the past 20 years, he has conducted more than 1,000 MRS brain scans of individuals with mood disorders, with the goal of characterizing the cross-sectional and longitudinal alterations in brain chemistry associated with mood disorders and their treatment. As Professor in the Department of Psychiatry, he has a notable publication record having served as an author on more than 300 publications. His research projects have been funded by the NIH for 18 years, including a NIDA K05 and a collaborative R01 grant.

    Board Certification and Academic Information

    Academic Departments Psychiatry -Primary
    Academic Divisions Adult Psychiatry
    Board Certification
    American Board of Psychiatry & Neurology (Psychiatry)

    Education history

    Graduate Training Business Administration - Bentley Ï㽶ÊÓƵ M.B.A.
    Neuroscience - Massachusetts General Hospital Fellow
    Residency Psychiatry - Massachusetts General Hospital Resident
    Internal Medicine - Brigham and Women's Hospital Intern
    Postdoctoral Fellowship Metabolic NMR - Ï㽶ÊÓƵ of Pennsylvania Postdoctoral Fellow
    Biophysics - Ï㽶ÊÓƵ of Pennsylvania Ph.D.
    Professional Medical Medicine - Ï㽶ÊÓƵ of Pennsylvania M.D.
    Chemistry - Massachusetts Institute of Technology S.B.

    Selected Publications

    Journal Article

    1. Saleh MG, Prescot A, Chang L, Cloak C, Cunningham E, Subramaniam P, Renshaw PF, Yurgelun-Todd D, Zllner HJ, Roberts TPL, Edden RAE, Ernst T (2023). Glutamate measurements using edited MRS. Magn Reson Med. ()
    2. Ma J, McGlade EC, Huber RS, Lyoo IK, Renshaw PF, Yurgelun-Todd DA (2023). Overweight/Obesity-related microstructural alterations of the fimbria-fornix in the ABCD study: The role of aerobic physical activity. PLoS One, 18(7), e0287682. ()
    3. Joo Y, Lee S, Hwang J, Kim J, Cheon YH, Lee H, Kim S, Yurgelun-Todd DA, Renshaw PF, Yoon S, Lyoo IK (2022). Differential alterations in brain structural network organization during addiction between adolescents and adults. Psychol Med, 53(9), 3805-3816. ()
    4. Sheth C, Huber RS, Renshaw PF, Yurgelun-Todd DA, McGlade EC (2022). Mild Traumatic Brain Injury and Behavior and Sleep Among 9- and 10-Year Old Children: Initial Findings From the Adolescent Brain Cognitive Development (ABCD) Study. J Early Adolesc, 43(6), 720-745. ()
    5. Huber RS, Boxer D, Smith CJ, Renshaw PF, Yurgelun-Todd DA, Kondo DG (2023). Detailed assessment of suicidal ideation in youth with bipolar disorder versus major depressive disorder. Bipolar Disord, 25(3), 200-208. ()
    6. Merritt K, McCutcheon RA, Aleman A, Ashley S, Beck K, Block W, Bloemen OJN, Borgan F, Boules C, Bustillo JR, Capizzano AA, Coughlin JM, David A, de la Fuente-Sandoval C, Demjaha A, Dempster K, Do KQ, Du F, Falkai P, Galiska-Skok B, Gallinat J, Gasparovic C, Ginestet CE, Goto N, Graff-Guerrero A, Ho BC, Howes O, Jauhar S, Jeon P, Kato T, Kaufmann CA, Kegeles LS, Keshavan MS, Kim SY, King B, Kunugi H, Lauriello J, Len-Ortiz P, Liemburg E, Mcilwain ME, Modinos G, Mouchlianitis E, Nakamura J, Nenadic I, ngr D, Ota M, Palaniyappan L, Pantelis C, Patel T, Plitman E, Posporelis S, Purdon SE, Reichenbach JR, Renshaw PF, Reyes-Madrigal F, Russell BR, Sawa A, Schaefer M, Shungu DC, Smesny S, Stanley JA, Stone J, Szulc A, Taylor R, Thakkar KN, Thberge J, Tibbo PG, van Amelsvoort T, Walecki J, Williamson PC, Wood SJ, Xin L, Yamasue H, McGuire P, Egerton A, 1H-MRS in Schizophrenia Investigators (2023). Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis. Mol Psychiatry. ()
    7. McGlade EC, Han DH, Kim SM, Shi X, Cline K, Yurgelun-Todd D, Renshaw PF (2022). Proton magnetic resonance spectroscopy (MRS) in individuals with internet gaming. Front Psychiatry, 13, 1031947. ()
    8. Huber RS, Sheth C, Renshaw PF, Yurgelun-Todd DA, McGlade EC (2020). Suicide Ideation and Neurocognition Among 9- and 10-Year Old Children in the Adolescent Brain Cognitive Development (ABCD) Study. Arch Suicide Res, 26(2), 641-655. ()
    9. Subramaniam P, Prescot A, McGlade E, Renshaw P, Yurgelun-Todd D (2022). Examination of gamma-aminobutyric acid and glutamate-glutamine levels in association with impulsive behavior in adolescent marijuana users. Drug Alcohol Depend, 233, 109326. ()
    10. Jeong H, Yoon S, Sung YH, Kim J, Lyoo IK, Yurgelun-Todd DA, Renshaw PF (2021). Effects of cytidine-5'-diphosphate choline on gray matter volumes in methamphetamine-dependent patients: A randomized, double-blind, placebo-controlled study. J Psychiatr Res, 143, 215-221. ()
    11. Palmer CE, Sheth C, Marshall AT, Adise S, Baker FC, Chang L, Clark DB, Coronado C, Dagher RK, Diaz V, Dowling GJ, Gonzalez MR, Haist F, Herting MM, Huber RS, Jernigan TL, LeBlanc K, Lee K, Lisdahl KM, Neigh G, Patterson MW, Renshaw P, Rhee KE, Tapert S, Thompson WK, Uban K, Sowell ER, Yurgelun-Todd D (2021). A Comprehensive Overview of the Physical Health of the Adolescent Brain Cognitive Development Study Cohort at Baseline. Front Pediatr, 9, 734184. ()
    12. Prescot A, Huber R, Kanekar S, Kondo D, Prisciandaro J, Ongur D, Renshaw PF (2021). Effect of moderate altitude on human cerebral metabolite levels: A preliminary, multi-site, proton magnetic resonance spectroscopy investigation. Psychiatry Res Neuroimaging, 314, 111314. ()
    13. Chaarani B, Hahn S, Allgaier N, Adise S, Owens MM, Juliano AC, Yuan DK, Loso H, Ivanciu A, Albaugh MD, Dumas J, Mackey S, Laurent J, Ivanova M, Hagler DJ, Cornejo MD, Hatton S, Agrawal A, Aguinaldo L, Ahonen L, Aklin W, Anokhin AP, Arroyo J, Avenevoli S, Babcock D, Bagot K, Baker FC, Banich MT, Barch DM, Bartsch H, Baskin-Sommers A, Bjork JM, Blachman-Demner D, Bloch M, Bogdan R, Bookheimer SY, Breslin F, Brown S, Calabro FJ, Calhoun V, Casey BJ, Chang L, Clark DB, Cloak C, Constable RT, Constable K, Corley R, Cottler LB, Coxe S, Dagher RK, Dale AM, Dapretto M, Delcarmen-Wiggins R, Dick AS, Do EK, Dosenbach NUF, Dowling GJ, Edwards S, Ernst TM, Fair DA, Fan CC, Feczko E, Feldstein-Ewing SW, Florsheim P, Foxe JJ, Freedman EG, Friedman NP, Friedman-Hill S, Fuemmeler BF, Galvan A, Gee DG, Giedd J, Glantz M, Glaser P, Godino J, Gonzalez M, Gonzalez R, Grant S, Gray KM, Haist F, Harms MP, Hawes S, Heath AC, Heeringa S, Heitzeg MM, Hermosillo R, Herting MM, Hettema JM, Hewitt JK, Heyser C, Hoffman E, Howlett K, Huber RS, Huestis MA, Hyde LW, Iacono WG, Infante MA, Irfanoglu O, Isaiah A, Iyengar S, Jacobus J, James R, Jean-Francois B, Jernigan T, Karcher NR, Kaufman A, Kelley B, Kit B, Ksinan A, Kuperman J, Laird AR, Larson C, LeBlanc K, Lessov-Schlagger C, Lever N, Lewis DA, Lisdahl K, Little AR, Lopez M, Luciana M, Luna B, Madden PA, Maes HH, Makowski C, Marshall AT, Mason MJ, Matochik J, McCandliss BD, McGlade E, Montoya I, Morgan G, Morris A, Mulford C, Murray P, Nagel BJ, Neale MC, Neigh G, Nencka A, Noronha A, Nixon SJ, Palmer CE, Pariyadath V, Paulus MP, Pelham WE, Pfefferbaum D, Pierpaoli C, Prescot A, Prouty D, Puttler LI, Rajapaske N, Rapuano KM, Reeves G, Renshaw PF, Riedel MC, Rojas P, de la Rosa M, Rosenberg MD, Ross MJ, Sanchez M, Schirda C, Schloesser D, Schulenberg J, Sher KJ, Sheth C, Shilling PD, Simmons WK, Sowell ER, Speer N, Spittel M, Squeglia LM, Sripada C, Steinberg J, Striley C, Sutherland MT, Tanabe J, Tapert SF, Thompson W, Tomko RL, Uban KA, Vrieze S, Wade NE, Watts R, Weiss S, Wiens BA, Williams OD, Wilbur A, Wing D, Wolff-Hughes D, Yang R, Yurgelun-Todd DA, Zucker RA, Potter A, Garavan HP, ABCD Consortium (2021). Baseline brain function in the preadolescents of the ABCD Study. Nat Neurosci, 24(8), 1176-1186. ()
    14. Kanekar S, Ettaro R, Hoffman MD, Ombach HJ, Brown J, Lynch C, Sheth CS, Renshaw PF (2021). Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression. Int J Mol Sci, 22(15). ()
    15. Han DH, Bae S, Hong J, Kim SM, Son YD, Renshaw P (2019). Resting-State fMRI Study of ADHD and Internet Gaming Disorder. J Atten Disord, 25(8), 1080-1095. ()
    16. Merritt K, McGuire PK, Egerton A, 1H-MRS in Schizophrenia Investigators, Aleman A, Block W, Bloemen OJN, Borgan F, Bustillo JR, Capizzano AA, Coughlin JM, De la Fuente-Sandoval C, Demjaha A, Dempster K, Do KQ, Du F, Falkai P, Galinska-Skok B, Gallinat J, Gasparovic C, Ginestet CE, Goto N, Graff-Guerrero A, Ho BC, Howes OD, Jauhar S, Jeon P, Kato T, Kaufmann CA, Kegeles LS, Keshavan M, Kim SY, Kunugi H, Lauriello J, Liemburg EJ, Mcilwain ME, Modinos G, Mouchlianitis ED, Nakamura J, Nenadic I, ngr D, Ota M, Palaniyappan L, Pantelis C, Plitman E, Posporelis S, Purdon SE, Reichenbach JR, Renshaw PF, Russell BR, Sawa A, Schaefer M, Shungu DC, Smesny S, Stanley JA, Stone JM, Szulc A, Taylor R, Thakkar K, Thberge J, Tibbo PG, van Amelsvoort T, Walecki J, Williamson PC, Wood SJ, Xin L, Yamasue H (2021). Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. JAMA Psychiatry, 78(6), 667-681. ()
    17. Li Y, Thompson WK, Reuter C, Nillo R, Jernigan T, Dale A, Sugrue LP, ABCD Consortium, Brown J, Dougherty RF, Rauschecker A, Rudie J, Barch DM, Calhoun V, Hagler D, Hatton S, Tanabe J, Marshall A, Sher KJ, Heeringa S, Hermosillo R, Banich MT, Squeglia L, Bjork J, Zucker R, Neale M, Herting M, Sheth C, Huber R, Reeves G, Hettema JM, Howlett KD, Cloak C, Baskin-Sommers A, Rapuano K, Gonzalez R, Karcher N, Laird A, Baker F, James R, Sowell E, Dick A, Hawes S, Sutherland M, Bagot K, Bodurka J, Breslin F, Morris A, Paulus M, Gray K, Hoffman E, Weiss S, Rajapakse N, Glantz M, Nagel B, Ewing SF, Goldstone A, Pfefferbaum A, Prouty D, Rosenberg M, Bookheimer S, Tapert S, Infante M, Jacobus J, Giedd J, Shilling P, Wade N, Uban K, Haist F, Heyser C, Palmer C, Kuperman J, Hewitt J, Cottler L, Isaiah A, Chang L, Edwards S, Ernst T, Heitzeg M, Puttler L, Sripada C, Iacono W, Luciana M, Clark D, Luna B, Schirda C, Foxe J, Freedman E, Mason M, McGlade E, Renshaw P, Yurgelun-Todd D, Albaugh M, Allgaier N, Chaarani B, Potter A, Ivanova M, Lisdahl K, Do E, Maes H, Bogdan R, Anokhin A, Dosenbach N, Glaser P, Heath A, Casey BJ, Gee D, Garavan HP, Dowling G, Brown S (2021). Rates of Incidental Findings in Brain Magnetic Resonance Imaging in Children. JAMA Neurol, 78(5), 578-587. ()
    18. Herting MM, Uban KA, Gonzalez MR, Baker FC, Kan EC, Thompson WK, Granger DA, Albaugh MD, Anokhin AP, Bagot KS, Banich MT, Barch DM, Baskin-Sommers A, Breslin FJ, Casey BJ, Chaarani B, Chang L, Clark DB, Cloak CC, Constable RT, Cottler LB, Dagher RK, Dapretto M, Dick AS, Dosenbach N, Dowling GJ, Dumas JA, Edwards S, Ernst T, Fair DA, Feldstein-Ewing SW, Freedman EG, Fuemmeler BF, Garavan H, Gee DG, Giedd JN, Glaser PEA, Goldstone A, Gray KM, Hawes SW, Heath AC, Heitzeg MM, Hewitt JK, Heyser CJ, Hoffman EA, Huber RS, Huestis MA, Hyde LW, Infante MA, Ivanova MY, Jacobus J, Jernigan TL, Karcher NR, Laird AR, LeBlanc KH, Lisdahl K, Luciana M, Luna B, Maes HH, Marshall AT, Mason MJ, McGlade EC, Morris AS, Nagel BJ, Neigh GN, Palmer CE, Paulus MP, Potter AS, Puttler LI, Rajapakse N, Rapuano K, Reeves G, Renshaw PF, Schirda C, Sher KJ, Sheth C, Shilling PD, Squeglia LM, Sutherland MT, Tapert SF, Tomko RL, Yurgelun-Todd D, Wade NE, Weiss SRB, Zucker RA, Sowell ER (2021). Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. Front Endocrinol (Lausanne), 11, 549928. ()
    19. Huber RS, McGlade EC, Legarreta M, Subramaniam P, Renshaw PF, Yurgelun-Todd DA (2020). Cingulate white matter volume and associated cognitive and behavioral impulsivity in Veterans with a history of suicide behavior. J Affect Disord, 281, 117-124. ()
    20. Legarreta MD, Sheth C, Prescot AP, Renshaw PF, McGlade EC, Yurgelun-Todd DA (2020). An exploratory proton MRS examination of gamma-aminobutyric acid, glutamate, and glutamine and their relationship to affective aspects of chronic pain. Neurosci Res, 163, 10-17. ()
    21. Kang I, Kondo D, Kim J, Lyoo IK, Yurgelun-Todd D, Hwang J, Renshaw PF (2020). Elevating the level of hypoxia inducible factor may be a new potential target for the treatment of depression. Med Hypotheses, 146, 110398. ()
    22. Prisciandaro JJ, Schacht JP, Prescot AP, Brenner HM, Renshaw PF, Brown TR, Anton RF (2019). Intraindividual changes in brain GABA, glutamate, and glutamine during monitored abstinence from alcohol in treatment-naive individuals with alcohol use disorder. Addict Biol, 25(6), e12810. ()
    23. Mastaloudis A, Sheth C, Hester SN, Wood SM, Prescot A, McGlade E, Renshaw PF, Yurgelun-Todd DA (2020). Supplementation with a putative calorie restriction mimetic micronutrient blend increases glutathione concentrations and improves neuroenergetics in brain of healthy middle-aged men and women. Free Radic Biol Med, 153, 112-121. ()
    24. Sheth C, Prescot AP, Legarreta M, Renshaw PF, McGlade E, Yurgelun-Todd D (2020). Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study. J Neurophysiol, 123(5), 1619-1629. ()
    25. Bakian AV, Huber RS, Scholl L, Renshaw PF, Kondo D (2020). Dietary creatine intake and depression risk among U.S. adults. Transl Psychiatry, 10(1), 52. ()
    26. Yurgelun-Todd DA, Renshaw PF, Goldsmith P, Uz T, Macek TA (2019). A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects. Psychopharmacology (Berl), 237(2), 317-328. ()
    27. Hagler DJ Jr, Hatton S, Cornejo MD, Makowski C, Fair DA, Dick AS, Sutherland MT, Casey BJ, Barch DM, Harms MP, Watts R, Bjork JM, Garavan HP, Hilmer L, Pung CJ, Sicat CS, Kuperman J, Bartsch H, Xue F, Heitzeg MM, Laird AR, Trinh TT, Gonzalez R, Tapert SF, Riedel MC, Squeglia LM, Hyde LW, Rosenberg MD, Earl EA, Howlett KD, Baker FC, Soules M, Diaz J, de Leon OR, Thompson WK, Neale MC, Herting M, Sowell ER, Alvarez RP, Hawes SW, Sanchez M, Bodurka J, Breslin FJ, Morris AS, Paulus MP, Simmons WK, Polimeni JR, van der Kouwe A, Nencka AS, Gray KM, Pierpaoli C, Matochik JA, Noronha A, Aklin WM, Conway K, Glantz M, Hoffman E, Little R, Lopez M, Pariyadath V, Weiss SR, Wolff-Hughes DL, DelCarmen-Wiggins R, Feldstein Ewing SW, Miranda-Dominguez O, Nagel BJ, Perrone AJ, Sturgeon DT, Goldstone A, Pfefferbaum A, Pohl KM, Prouty D, Uban K, Bookheimer SY, Dapretto M, Galvan A, Bagot K, Giedd J, Infante MA, Jacobus J, Patrick K, Shilling PD, Desikan R, Li Y, Sugrue L, Banich MT, Friedman N, Hewitt JK, Hopfer C, Sakai J, Tanabe J, Cottler LB, Nixon SJ, Chang L, Cloak C, Ernst T, Reeves G, Kennedy DN, Heeringa S, Peltier S, Schulenberg J, Sripada C, Zucker RA, Iacono WG, Luciana M, Calabro FJ, Clark DB, Lewis DA, Luna B, Schirda C, Brima T, Foxe JJ, Freedman EG, Mruzek DW, Mason MJ, Huber R, McGlade E, Prescot A, Renshaw PF, Yurgelun-Todd DA, Allgaier NA, Dumas JA, Ivanova M, Potter A, Florsheim P, Larson C, Lisdahl K, Charness ME, Fuemmeler B, Hettema JM, Maes HH, Steinberg J, Anokhin AP, Glaser P, Heath AC, Madden PA, Baskin-Sommers A, Constable RT, Grant SJ, Dowling GJ, Brown SA, Jernigan TL, Dale AM (2019). Image processing and analysis methods for the Adolescent Brain Cognitive Development Study. Neuroimage, 202, 116091. ()
    28. Hwang J, DeLisi LE, ngr D, Riley C, Zuo C, Shi X, Sung YH, Kondo D, Kim TS, Villafuerte R, Smedberg D, Yurgelun-Todd D, Renshaw PF (2019). Cerebral bioenergetic differences measured by phosphorus-31 magnetic resonance spectroscopy between bipolar disorder and healthy subjects living in two different regions suggesting possible effects of altitude. Psychiatry Clin Neurosci, 73(9), 581-589. ()
    29. Prisciandaro JJ, Schacht JP, Prescot AP, Brenner HM, Renshaw PF, Brown TR, Anton RF (2019). Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment naïve individuals with alcohol use disorder. Neurosci Lett, 706, 207-210. ()
    30. Huber RS, Subramaniam P, Kondo DG, Shi X, Renshaw PF, Yurgelun-Todd DA (2018). Reduced lateral orbitofrontal cortex volume and suicide behavior in youth with bipolar disorder. Bipolar Disord, 21(4), 321-329. ()
    31. Sabic H, Kious B, Boxer D, Fitzgerald C, Riley C, Scholl L, McGlade E, Yurgelun-Todd D, Renshaw PF, Kondo DG (2019). Effect of Altitude on Veteran Suicide Rates. High Alt Med Biol, 20(2), 171-177. ()
    32. Sheth C, Prescot AP, Legarreta M, Renshaw PF, McGlade E, Yurgelun-Todd D (2019). Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma. J Affect Disord, 248, 166-174. ()
    33. Ombach HJ, Scholl LS, Bakian AV, Renshaw KT, Sung YH, Renshaw PF, Kanekar S (2019). Association between altitude, prescription opioid misuse, and fatal overdoses. Addict Behav Rep, 9, 100167. ()
    34. Prisciandaro JJ, Schacht JP, Prescot AP, Renshaw PF, Brown TR, Anton RF (2019). Brain Glutamate, GABA, and Glutamine Levels and Associations with Recent Drinking in Treatment-Naïve Individuals with Alcohol Use Disorder Versus Light Drinkers. Alcohol Clin Exp Res, 43(2), 221-226. ()
    35. Curtin K, Fleckenstein AE, Keeshin BR, Yurgelun-Todd DA, Renshaw PF, Smith KR, Hanson GR (2018). Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology, 43(13), 2548-2555. ()
    36. Han DH, Yoo M, Renshaw PF, Petry NM (2018). A cohort study of patients seeking Internet gaming disorder treatment. J Behav Addict, 7(4), 930-938. ()
    37. Prescot AP, Prisciandaro JJ, Miller SR, Ingenito G, Kondo DG, Renshaw PF (2018). Two-Dimensional Proton Magnetic Resonance Spectroscopy versus J-Editing for GABA Quantification in Human Brain: Insights from a GABA-Aminotransferase Inhibitor Study. Sci Rep, 8(1), 13200. ()
    38. Kanekar S, Sheth CS, Ombach HJ, Olson PR, Bogdanova OV, Petersen M, Renshaw CE, Sung YH, DAnci KE, Renshaw PF (2018). Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline. Pharmacol Biochem Behav, 170, 25-35. ()
    39. Sheth C, Prescot A, Bueler E, DiMuzio J, Legarreta M, Renshaw PF, Yurgelun-Todd D, McGlade E (2018). Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging, 276, 24-32. ()
    40. Kang KD, Han DH, Kim SM, Bae S, Renshaw PF (2016). The Correlation Between Cognitive and Movement Shifting and Brain Activity in Children With ADHD. J Atten Disord, 22(7), 661-670. ()
    41. Yoon S, Kim J, Musen G, Renshaw PF, Hwang J, Bolo NR, Kim JE, Simonson DC, Weinger K, Ryan CM, Lyoo IK, Jacobson AM (2017). Prefronto-temporal white matter microstructural alterations 20 years after the diagnosis of type 1 diabetes mellitus. Pediatr Diabetes, 19(3), 478-485. ()
    42. Sheth C, Ombach H, Olson P, Renshaw PF, Kanekar S (2018). Increased Anxiety and Anhedonia in Female Rats Following Exposure to Altitude. High Alt Med Biol, 19(1), 81-90. ()
    43. Prescot AP, Miller SR, Ingenito G, Huber RS, Kondo DG, Renshaw PF (2017). In Vivo Detection of CPP-115 Target Engagement in Human Brain. Neuropsychopharmacology, 43(3), 646-654. ()
    44. Kim JE, Kim GH, Hwang J, Kim JY, Renshaw PF, Yurgelun-Todd DA, Kim B, Kang I, Jeon S, Ma J, Lyoo IK, Yoon S (2016). Metabolic alterations in the anterior cingulate cortex and related cognitive deficits in late adolescent methamphetamine users. Addict Biol, 23(1), 327-336. ()
    45. Huber RS, Kondo DG, Shi XF, Prescot AP, Clark E, Renshaw PF, Yurgelun-Todd DA (2017). Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder. J Affect Disord, 225, 71-78. ()
    46. Prescot A, Sheth C, Legarreta M, Renshaw PF, McGlade E, Yurgelun-Todd D (2018). Altered Cortical GABA in Female Veterans with Suicidal Behavior: Sex Differences and Clinical Correlates. Chronic Stress (Thousand Oaks), 2. ()
    47. Bae S, Han DH, Jung J, Nam KC, Renshaw PF (2017). Comparison of brain connectivity between Internet gambling disorder and Internet gaming disorder: A preliminary study. J Behav Addict, 6(4), 505-515. ()
    48. Prisciandaro JJ, Tolliver BK, Prescot AP, Brenner HM, Renshaw PF, Brown TR, Anton RF (2017). Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry, 7(7), e1163. ()
    49. Son YD, Han DH, Kim SM, Min KJ, Renshaw PF (2017). A functional connectivity comparison between attention deficit hyperactivity disorder and bipolar disorder in medication-naïve adolescents with mood fluctuation and attention problems. Psychiatry Res Neuroimaging, 263, 1-7. ()
    50. Han DH, Kim SM, Bae S, Renshaw PF, Anderson JS (2015). Brain connectivity and psychiatric comorbidity in adolescents with Internet gaming disorder. Addict Biol, 22(3), 802-812. ()
    51. Harper DG, Jensen JE, Ravichandran C, Perlis RH, Fava M, Renshaw PF, Iosifescu DV (2016). Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. Neuropsychopharmacology, 42(4), 876-885. ()
    52. Kang KD, Han DH, Kim SM, Bae S, Renshaw PF (2016). The correlation between cognitive and movement shifting and brain activity in children with ADHD. J Atten Disord, 1-10.
    53. Kim JE, Kim GH, Hwang J, Kim JY, Renshaw PF, Yurgelun-Todd DA, Kim B, Kang I, Jeon S, Ma J, Lyoo IK, Yoon S (2016). Metabolic alterations in the anterior cingulate cortex and related cognitive deficits in late adolescent methamphetamine users. Addict Biol.
    54. Yoon S, Kim JE, Hwang J, Kim TS, Kang HJ, Namgung E, Ban S, Oh S, Yang J, Renshaw PF, Lyoo IK (2015). Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder. Biol Psychiatry, 80(6), 439-447. ()
    55. Aydin B, Yurt A, Gkmen N, Renshaw P, Olson D, Yildiz A (2016). Trait-related alterations of N-acetylaspartate in euthymic bipolar patients: A longitudinal proton magnetic resonance spectroscopy study. J Affect Disord, 206, 315-320.
    56. Bae S, Han DH, Kim SM, Shi X, Renshaw PF (2016). Neurochemical correlates of internet game play in adolescents with attention deficit hyperactivity disorder: A proton magnetic resonance spectroscopy (MRS) study. Psychiatry Res Neuroimaging, 254, 10-7. ()
    57. Kondo DG, Forrest LN, Shi X, Sung YH, Hellem TL, Huber RS, Renshaw PF (2016). Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids, 48(8), 1941-54. ()
    58. Jeong BS, Han DH, Kim SM, Lee SW, Renshaw PF (2015). White matter connectivity and Internet gaming disorder. Addict Biol, 21(3), 732-42. ()
    59. Han DH, Kim SM, Bae S, Renshaw PF, Anderson JS (2016). A failure of suppression within the default mode network in depressed adolescents with compulsive internet game play. J Affect Disord, 194, 57-64. ()
    60. Chung US, Han DH, Shin YJ, Renshaw PF (2016). A prosocial online game for social cognition training in adolescents with high-functioning autism: an fMRI study. Neuropsychiatr Dis Treat, 12, 651-60.
    61. Prisciandaro JJ, Schacht JP, Prescot AP, Renshaw PF, Brown TR, Anton RF (2016). Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence. Alcohol Clin Exp Res, 40(3), 491-6. ()
    62. Yildiz A, Aydin B, Gkmen N, Yurt A, Cohen B, Keskinoglu P, ngr D, Renshaw P (2016). Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry Cogn Neurosci Neuroimaging, 1(2), 125-131.
    63. Lyoo IK, Yoon S, Kim TS, Lim SM, Choi Y, Kim JE, Hwang J, Jeong HS, Cho HB, Chung YA, Renshaw PF (2015). Predisposition to and effects of methamphetamine use on the adolescent brain. Mol Psychiatry, 20(12), 1516-24. ()
    64. Shi XF, Carlson PJ, Sung YH, Fiedler KK, Forrest LN, Hellem TL, Huber RS, Kim SE, Zuo C, Jeong EK, Renshaw PF, Kondo DG (2015). Decreased brain PME/PDE ratio in bipolar disorder: a preliminary (31) P magnetic resonance spectroscopy study. Bipolar Disord, 17(7), 743-52. ()
    65. Bogdanov VB, Vigan A, Noirhomme Q, Bogdanova OV, Guy N, Laureys S, Renshaw PF, Dallel R, Phillips C, Schoenen J (2014). Cerebral responses and role of the prefrontal cortex in conditioned pain modulation: an fMRI study in healthy subjects. Behav Brain Res, 281, 187-98. ()
    66. Kanekar S, Bogdanova OV, Olson PR, Sung YH, DAnci KE, Renshaw PF (2015). Hypobaric hypoxia induces depression-like behavior in female Sprague-Dawley rats, but not in males. High Alt Med Biol, 16(1), 52-60. ()
    67. Han JW, Han DH, Bolo N, Kim B, Kim BN, Renshaw PF (2014). Differences in functional connectivity between alcohol dependence and internet gaming disorder. Addict Behav, 41, 12-9. ()
    68. Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF (2015). Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. J Dual Diagn, 11(3-4), 189-202. ()
    69. Plante DT, Trksak GH, Jensen JE, Penetar DM, Ravichandran C, Riedner BA, Tartarini WL, Dorsey CM, Renshaw PF, Lukas SE, Harper DG (2014). Gray matter-specific changes in brain bioenergetics after acute sleep deprivation: a 31P magnetic resonance spectroscopy study at 4 Tesla. Sleep, 37(12), 1919-27. ()
    70. Huber RS, Kim N, Renshaw CE, Renshaw PF, Kondo DG (2014). Relationship between altitude and lithium in groundwater in the United States of America: results of a 1992-2003 study. Geospat Health, 9(1), 231-5. ()
    71. Darlington TM, Pimentel R, Smith K, Bakian AV, Jerominski L, Cardon J, Camp NJ, Callor WB, Grey T, Singleton M, Yandell M, Renshaw PF, Yurgelun-Todd DA, Gray D, Coon H (2014). Identifying rare variants for genetic risk through a combined pedigree and phenotype approach: application to suicide and asthma. Transl Psychiatry, 4(10), e471. ()
    72. Jeong EK, Sung YH, Kim SE, Zuo C, Shi X, Mellon EA, Renshaw PF (2010). Measurement of creatine kinase reaction rate in human brain using magnetization transfer image-selected in vivo spectroscopy (MT-ISIS) and a volume ³¹P/¹H radiofrequency coil in a clinical 3-T MRI system. NMR Biomed, 24(7), 765-70. ()
    73. Agarwal N, Sung YH, Jensen JE, daCunha G, Harper D, Olson D, Renshaw PF (2010). Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T. Bipolar Disord, 12(8), 825-33. ()

    Review

    1. Ma J, Lyoo IK, Renshaw PF, Yurgelun-Todd DA (2022). Effect of cannabinoids on brain metabolites: A review of animal and human studies. [Review]. Exp Clin Psychopharmacol, 31(1), 248-262. ()
    2. Smith CJ, Renshaw P, Yurgelun-Todd D, Sheth C (2022). Acute and chronic neuropsychiatric symptoms in novel coronavirus disease 2019 (COVID-19) patients: A qualitative review. [Review]. Front Public Health, 10, 772335. ()
    3. Kious BM, Kondo DG, Renshaw PF (2019). Creatine for the Treatment of Depression. [Review]. Biomolecules, 9(9). ()
    4. Kious BM, Kondo DG, Renshaw PF (2018). Living High and Feeling Low: Altitude, Suicide, and Depression. [Review]. Harv Rev Psychiatry, 26(2), 43-56. ()
    5. Riley CA, Renshaw PF (2017). Brain choline in major depression: A review of the literature. [Review]. Psychiatry Res Neuroimaging, 271, 142-153. ()
    6. Gould TD, Georgiou P, Brenner LA, Brundin L, Can A, Courtet P, Donaldson ZR, Dwivedi Y, Guillaume S, Gottesman II, Kanekar S, Lowry CA, Renshaw PF, Rujescu D, Smith EG, Turecki G, Zanos P, Zarate CA Jr, Zunszain PA, Postolache TT (2017). Animal models to improve our understanding and treatment of suicidal behavior. [Review]. Transl Psychiatry, 7(4), e1092. ()
    7. Hellem T, Shi X, Latendresse G, Renshaw PF (2015). The Utility of Magnetic Resonance Spectroscopy for Understanding Substance Use Disorders: A Systematic Review of the Literature. [Review]. J Am Psychiatr Nurses Assoc, 21(4), 244-75. ()
    8. Hellem TL, Lundberg KJ, Renshaw PF (2015). A review of treatment options for co-occurring methamphetamine use disorders and depression. [Review]. J Addict Nurs, 26(1), 14-23; quiz E1. ()

    Patent

    1. Yurgelun-Todd, Deborah, Renshaw, Perry (2019). Methods and compositions for improving cognitive performance 20100041621.
    2. Renshaw, Perry, Yurgelun-Todd, Deborah (2019). Methods for improving frontal brain bioenergetic metabolism 20100041620.
    3. Renshaw P, Yurgelun-Todd D (2019). Combination of Creatine, an Omega-3 Fatty Acid, and Citicoline. U.S. Patent No. PCT/US2015/014856. Washington, D.C.:U.S. Patent and Trademark Office.
    4. Rohan ML, Renshaw PF, Parrow A (2014). Magnetic field treatment techniques. U.S. Patent No. 8,702,582. Washington, D.C.:U.S. Patent and Trademark Office.
    5. Renshaw PF (2014). Predicting efficacy of psychiatric treatment. U.S. Patent No. 8,694,073. Washington, D.C.:U.S. Patent and Trademark Office.
    6. Renshaw PF (2013). Compounds for the treatment of psychiatric of substance abuse disorders. U.S. Patent No. 8,575,219. Washington, D.C.:U.S. Patent and Trademark Office.
    7. Yurgelun-Todd DA, Renshaw PF (2013). Use of secretin in treatments of disorders associated with amygdala. U.S. Patent No. 8,524,655. Washington, D.C.:U.S. Patent and Trademark Office.
    8. Rohan ML, Renshaw PF, Parrow A (2012). Magentc field treatment techniques. U.S. Patent No. 8,303,480. Washington, D.C.:U.S. Patent and Trademark Office.
    9. Renshaw PF (2011). Compounds for the treatment of psychiatric substance abuse disorders. U.S. Patent No. 7,863,254. Washington, D.C.:U.S. Patent and Trademark Office.
    10. Renshaw PF (2011). Compounds for the treatment of psychiatric or substance abuse disorders. U.S. Patent No. 8,030,294. Washington, D.C.:U.S. Patent and Trademark Office.
    11. Rohan ML, Renshaw PF, Parrow A (2011). Magnetic filed treatment techniques. U.S. Patent No. 8,047,979. Washington, D.C.:U.S. Patent and Trademark Office.
    12. Lukas SE, Renshaw PF (2011). Compounds for the treatment of marihuana dependence, withdrawal, and usage. U.S. Patent No. 7,947,611. Washington, D.C.:U.S. Patent and Trademark Office.
    13. Lukas SE, Renshaw PF (2010). Compounds for the treatment of marijuana dependence, withdrawal, and usage. U.S. Patent No. 7,947,661. Washington, D.C.:U.S. Patent and Trademark Office.
    14. Rohan ML, Parow A, Renshaw PF (2007). Magnetic field stimulation techniques. U.S. Patent No. 7,282,021. Washington, D.C.:U.S. Patent and Trademark Office.
    15. Rohan ML, Parow A, Renshaw PF (2006). Magnetic field stimulation techniques. U.S. Patent No. 7,033,312. Washington, D.C.:U.S. Patent and Trademark Office.
    16. Rohan ML, Renshaw PF, Parow A (2006). Magnetic field treatment techniques. U.S. Patent No. 8,047,979. Washington, D.C.:U.S. Patent and Trademark Office.
    17. Anderson CM, Lowen SB, Renshaw PF, Teicher MH, Maas LC (2005). Method for providing optimal drug dosage. U.S. Patent No. 6,898,455. Washington, D.C.:U.S. Patent and Trademark Office.
    18. Renshaw PF (2004). Pyrimidines, such as uridine, in treatments for patients with bipolar disorder. U.S. Patent No. 6,898,455. Washington, D.C.:U.S. Patent and Trademark Office.
    19. Ke Y, Renshaw PF, Cohen BM (2003). Two-dimensional MR spectroscopy techniques. U.S. Patent No. 6,617,169. Washington, D.C.:U.S. Patent and Trademark Office.
    20. Renshaw PF, Parow AM, Rohan M (2003). Magnetic field stimulation techniques. U.S. Patent No. 6,572.528. Washington, D.C.:U.S. Patent and Trademark Office.
    21. Renshaw PF (2003). Method and apparatus for detecting mental illness. U.S. Patent No. 6 ,400,978. Washington, D.C.:U.S. Patent and Trademark Office.
    22. Renshaw PF, Cowan RL, Frederick B (2003). Method for assessing cortical response to blue light. U.S. Patent No. 6,630.127. Washington, D.C.:U.S. Patent and Trademark Office.
    23. Renshaw PF (2000). Treatment of mental conditions including depression. U.S. Patent No. 6,258,794. Washington, D.C.:U.S. Patent and Trademark Office.
    24. Renshaw PF, Lukas SE (2000). Cytidine-containing and cytosine-containing compounds as a treatment for stimulant exposure. CIP 6,103,703. (Applications pending for use in depression, alcohol abuse/dependence, and ADHD.). U.S. Patent No. 5,958,896. Washington, D.C.:U.S. Patent and Trademark Office.
    25. Frederick B, Wald L, Renshaw PF (2000). Phased array echo-planer imaging system for fMRI. U.S. Patent No. 6,104,943. Washington, D.C.:U.S. Patent and Trademark Office.
    26. Renshaw PF, Lukas SE (2000). Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure. U.S. Patent No. 6,103,703. Washington, D.C.:U.S. Patent and Trademark Office.
    27. Maas LC, Frederick B, Renshaw PF (1998). Decoupled automated rotational and translational registration for functional MRI time series data: the DART registration algorithm. U.S. Patent No. 5,850,486. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    News

    Podcasts